Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
22.51
-0.32 (-1.42%)
Nov 7, 2025, 9:44 AM EST - Market open
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $15.00M in the twelve months ending September 30, 2025, up 118.88% year-over-year.
Revenue (ttm)
$15.00M
Revenue Growth
+118.88%
P/S Ratio
202.87
Revenue / Employee
$194,805
Employees
77
Market Cap
3.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CNTA News
- 1 hour ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 days ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - GlobeNewsWire
- 4 months ago - Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist - GlobeNewsWire
- 5 months ago - Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year - GlobeNewsWire
- 6 months ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 - GlobeNewsWire